Literature DB >> 9674829

Long-term selective IgG immuno-adsorption improves Rasmussen's encephalitis.

C Antozzi1, T Granata, N Aurisano, G Zardini, P Confalonieri, G Airaghi, R Mantegazza, R Spreafico.   

Abstract

We report that long-term selective immunoglobulin G immunoadsorption by protein A (PAI) improved seizure frequency and neuropsychological deficits in a 16-year-old patient with severe treatment-resistant Rasmussen's encephalitis (RE). Clinical improvement correlated with reduction of antiglutamate receptor 3 antibodies. The efficacy of PAI in our patient supports the autoimmune hypothesis of RE and suggests its application to avoid, or at least delay, functional hemispherectomy in selected cases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674829     DOI: 10.1212/wnl.51.1.302

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

Review 1.  Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.

Authors:  Sophia Varadkar; Christian G Bien; Carol A Kruse; Frances E Jensen; Jan Bauer; Carlos A Pardo; Angela Vincent; Gary W Mathern; J Helen Cross
Journal:  Lancet Neurol       Date:  2014-02       Impact factor: 44.182

2.  GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins.

Authors:  K D Whitney; J O McNamara
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

Review 3.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

4.  GluR3B Antibody Was a Biomarker for Drug-Resistant Epilepsy in Patients With Focal to Bilateral Tonic-Clonic Seizures.

Authors:  Qingwei Lai; Qingyun Li; Xinyu Li; Heng Wang; Wei Zhang; Xiaotao Song; Peng Hu; Ruiqin Yao; Hongbin Fan; Xingshun Xu
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

5.  Modulation of Immunity and the Inflammatory Response: A New Target for Treating Drug-resistant Epilepsy.

Authors:  Nian Yu; Hao Liu; Qing Di
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.